Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. / Østergaard, H. B.; Mandrup-Poulsen, T.; Berkelmans, G. F.N.; van der Graaf, Y.; Visseren, F. L.J.; Westerink, J.
In: Diabetes and Metabolism, Vol. 45, No. 3, 2019, p. 254-260.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients
AU - Østergaard, H. B.
AU - Mandrup-Poulsen, T.
AU - Berkelmans, G. F.N.
AU - van der Graaf, Y.
AU - Visseren, F. L.J.
AU - Westerink, J.
PY - 2019
Y1 - 2019
N2 - Background: The haemoglobin glycation index (HGI)has been proposed as a marker of interindividual differences in haemoglobin glycosylation. Previous studies have shown a relationship between high HGI and risk of cardiovascular disease (CVD)in patients with diabetes. However, no studies have investigated the role of previous CVD in this association. Methods: The study cohort comprised patients with type 2 diabetes mellitus (T2DM; n = 1910)included in the Second Manifestations of Arterial Disease (SMART)study. The relationship between either HGI or HbA1c and a composite of cardiovascular events as the primary outcome, and mortality, cardiovascular mortality, myocardial infarction and stroke as secondary outcomes, was investigated using Cox proportional-hazards models. Similar analyses were performed after stratification according to previous CVD. Results: A 1-unit higher HGI was associated with a 29% greater risk of a composite of cardiovascular events (HR: 1.29, 95% CI: 1.06–1.57)in patients without previous CVD, whereas no such relationship was seen in patients with previous CVD (HR: 0.96, 95% CI: 0.86–1.08). The direction and magnitude of the hazard ratios (HRs)of HGI and HbA1c in relation to outcomes were similar. Additional adjustment for HbA1c in the association between HGI and outcomes lowered the HRs. Conclusion: Similar to HbA1c, higher HGI is related to higher risk of cardiovascular events in patients with T2DM without CVD. As HbA1c has proved to be a comparable risk factor, and obtaining and interpreting the HGI is complicated, any additional benefit of applying the HGI in clinical settings is likely to be limited.
AB - Background: The haemoglobin glycation index (HGI)has been proposed as a marker of interindividual differences in haemoglobin glycosylation. Previous studies have shown a relationship between high HGI and risk of cardiovascular disease (CVD)in patients with diabetes. However, no studies have investigated the role of previous CVD in this association. Methods: The study cohort comprised patients with type 2 diabetes mellitus (T2DM; n = 1910)included in the Second Manifestations of Arterial Disease (SMART)study. The relationship between either HGI or HbA1c and a composite of cardiovascular events as the primary outcome, and mortality, cardiovascular mortality, myocardial infarction and stroke as secondary outcomes, was investigated using Cox proportional-hazards models. Similar analyses were performed after stratification according to previous CVD. Results: A 1-unit higher HGI was associated with a 29% greater risk of a composite of cardiovascular events (HR: 1.29, 95% CI: 1.06–1.57)in patients without previous CVD, whereas no such relationship was seen in patients with previous CVD (HR: 0.96, 95% CI: 0.86–1.08). The direction and magnitude of the hazard ratios (HRs)of HGI and HbA1c in relation to outcomes were similar. Additional adjustment for HbA1c in the association between HGI and outcomes lowered the HRs. Conclusion: Similar to HbA1c, higher HGI is related to higher risk of cardiovascular events in patients with T2DM without CVD. As HbA1c has proved to be a comparable risk factor, and obtaining and interpreting the HGI is complicated, any additional benefit of applying the HGI in clinical settings is likely to be limited.
KW - Cardiovascular disease
KW - Diabetes mellitus type 2
KW - Glycaemic control
KW - Haemoglobin glycation index
KW - HbA
KW - HGI
U2 - 10.1016/j.diabet.2018.04.006
DO - 10.1016/j.diabet.2018.04.006
M3 - Journal article
C2 - 29784563
AN - SCOPUS:85047219438
VL - 45
SP - 254
EP - 260
JO - Diabetes & Metabolism
JF - Diabetes & Metabolism
SN - 1262-3636
IS - 3
ER -
ID: 220845401